<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19578">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852018</url>
  </required_header>
  <id_info>
    <org_study_id>PROG/10/77</org_study_id>
    <nct_id>NCT02852018</nct_id>
  </id_info>
  <brief_title>Identification of Genetic Markers Modulating Rhythmic Risk Among Patients With Severe Cardiomyopathy</brief_title>
  <acronym>GENECHOC</acronym>
  <official_title>Identification of Genetic Markers Modulating Rhythmic Risk Among Patients With Severe Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to identify common genetic polymorphisms associated with the
      occurrence of rhythmic events in patients with severe cardiomyopathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Prevalence of polymorphisms pre-selected candidates (or by direct sequencing by High Resolution Melting).</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of polymorphisms frequent (&gt; 5% in the general population) by association study ( &quot;Genome Wide Association Study '(GWAS)) using genotyping technology broadband Axiom (Affymetrix).</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Appropriate treatment</arm_group_label>
    <description>Patients who have a rhythmic event (before or after inclusion) appropriately treated either by administering an electric shock or by antiarrhythmic stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No event</arm_group_label>
    <description>Patients who have never received treatment or electrical antiarrhythmic stimulation and with a minimum follow-up of three years before inclusion and did not receive appropriate treatment during the follow up period of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Identification of genetic polymorphisms</intervention_name>
    <arm_group_label>Appropriate treatment</arm_group_label>
    <arm_group_label>No event</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Genetic analysis will compare 500 patients implanted with an ICD for primary prevention
        and having received an appropriate shock and another 500 patients implanted with an ICD
        for primary prevention and have not received appropriate shock after a minimum follow-up
        three years before inclusion. To allow the matching of two groups, it requires to recruit
        500 patients in the &quot;appropriate treatment&quot; group and 1000 patients in the &quot;no event&quot;
        group.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients implanted for primary prevention, an implantable cardioverter defibrillator
             (ICD) single or double room, for severe cardiomyopathy (EF &lt;35%)

          -  Patients with ischemic cardiomyopathy or idiopathic dilated cardiomyopathy.-
             &quot;Appropriate treatment&quot; group: patients who had a rhythmic event (before or after
             inclusion) appropriately treated either by administering an electric shock or by
             antiarrhythmic stimulation

          -  Group &quot;no event&quot; patients who have never received treatment or electrical
             antiarrhythmic stimulation and with a minimum follow-up of three years before
             inclusion and did not receive proper treatment during the follow up period of the
             study

        Exclusion Criteria:

          -  Patients implanted with an ICD for primary prevention in the context of a family
             hereditary disease (long QT syndrome, Brugada syndrome, hypertrophic cardiomyopathy,
             ventricular tachycardia catecholergic right ventricular dysplasia ...).

          -  Patients with left ventricular function greater than 35%.

          -  Patients implanted with a defibrillator function resynchronization.

          -  Patients minors, adults under guardianship and protected persons are eligible under
             this project.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vincent Probst, Pu-PH</last_name>
    <phone>0033 2 40 16 50 08</phone>
    <email>vincent.probst@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean- Marc Dupuis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre BORDACHAR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques MANSOURATI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand.</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique LAMAISON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel LAURENT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>.Pascal DEFAYE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Bru</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier KLUG</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe CHEVALIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Claude DEHARO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Luc PASQUIE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas SADOUL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Probst</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MABO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric ANSELME</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence JESEL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MAURY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique BABUTY</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 28, 2016</lastchanged_date>
  <firstreceived_date>July 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
